

PHA5878C: Patient Care 3 Introduction to Cardiovascular and Pulmonary Disease

Fall 2025 | 6 Credit Hours – [A-E Grading]

This is the third of an eight-course sequence that prepares the student to provide patient-centered care by serving as a collaborative interprofessional team-member who is an authority on pharmacotherapy. This course focuses on providing patient-centered care to patients who have cardiovascular and pulmonary disorders. Learners will develop, integrate, and apply knowledge from the foundational disciplines (i.e., pharmaceutical, social/behavioral/administrative, and clinical sciences) and apply the Pharmacists’ Patient Care Process in solving case-based scenarios of patients with cardiovascular and pulmonary diseases.

Course Prerequisites: Completion of all Year 1 Pharm.D. program coursework including milestones.

Course Corequisites: PHA5163L Professional Practice Skills Laboratory 3

Course Faculty and Staff	
Course Director	Instructional Designer
Katie Vogel Anderson, Pharm.D., Ph.D., BCACP, FCCP 352-294-5420 kvanderson@cop.ufl.edu	Skylar Johnson, M.A. sky@cop.ufl.edu
Academic Coordinators	
Morgan Milner (GNV) Email: morgan.milner@ufl.edu	Jessica Linares (ORL) Email: jnoriegalinares@ufl.edu
Jaime Welsh (JAX) Email: jaimewelsh@ufl.edu	Nadja Rivera (ORL) Email: nl.riverarivera@ufl.edu
Teaching Faculty	
Jane Aldrich, PhD Email: janealdrich@ufl.edu	Kaitlin Alexander, PharmD, BCCCP Email: kaitlin.alexander@cop.ufl.edu
Francine Azeredo, BPharm, PhD Email: francinej@ufl.edu	Erin Bruce, PhD Email: ebruce5@ufl.edu
Lauren Carpenter, PharmD Email: l.carpenter@ufl.edu	Larisa Cavallari, PharmD, BCPS, FCCP Email: lcavallari@ufl.edu
David DeRemer, PharmD, BCOP, FCCP, FHOPA Email: dderemer@cop.ufl.edu	Eric Dietrich, PharmD, BCACP, CPC-A, CEMC, CPB Email: dietrich@cop.ufl.edu
Julio Duarte, PharmD, PhD Email: juliod@cop.ufl.edu	Michelle Farland, PharmD Email: mfarland@cop.ufl.edu
Je-Won “Jennifer” Hong, PharmD Email: jewonhong@ufl.edu	Sebastian Jugl, B.S.Pharm, RPh Email: s.jugl@cop.ufl.edu
Xingui Liu, PhD Email: xliu@cop.ufl.edu	Carol Motycka, PharmD, CHSE Email: motycka@cop.ufl.edu
Khoa Nguyen, PharmD Email: Nguyen.khoa@ufl.edu	Bradley Phillips, PharmD, BCACP Email: bradnp@cop.ufl.edu
Mohamed Radwan, PhD Email: radwanm@ufl.edu	Teresa Roane, PharmD, MBA, BCACP Email: teroane@ufl.edu
Guangrong Zheng, PhD Email: zhengg@ufl.edu	

[Faculty and Staff: Who to Contact and Questions to Ask](#)

Office Hours: Please see the Canvas course site for posted office hours.

Faculty Locations:

Gainesville	PTR: MSB 0445, PG-22 PEP: HPNP 2336 POP: DSIT 5th floor	CSP: MSB P1-20 MC: MSB P3-12
Jacksonville	Tower 2, First Floor	
Orlando	UFRAC 420	

Course Objectives and Educational Outcomes

Course Objectives Upon completion of this course, the student will be able to:	Linked Educational Outcome
Given a case of a patient with one or more of the above disorders/pharmacotherapy needs, integrate knowledge and use clinical reasoning skills to accomplish the following steps:	
<ol style="list-style-type: none"> 1. Collect: Gather subjective and objective information and analyze the data to understand the relevant medical/medication history and clinical status of the patient. <ol style="list-style-type: none"> a. Subjective and objective information is collected through comprehensive medication review with the patient, medical record review, pharmacy profile review, and communication with other members of the health care team. b. A holistic view is initiated during collection in order to consider physiological, psychological, and sociological variables of the patient and this view is maintained throughout the patient care process. 	Provider Professional
<ol style="list-style-type: none"> 2. Assess: Assess the information collected and formulate a problem list consisting of the patient's active medical problems and medication therapy problems in order to prioritize medication therapy recommendations to achieve the patient's overall health goals. <ol style="list-style-type: none"> a. Assess the patient's active medical conditions, taking into account clinical and patient goals of therapy. b. Assess the indication, effectiveness, safety, adherence and convenience (administration, access, affordability) of each medication the patient is taking. c. Include in the assessment an evaluation of risk factors, relevant psychosocial issues, and the need for preventative care or for referral to another healthcare practitioner for further evaluation d. Formulate a medication therapy problem list, classifying the patient's medication therapy problems based on indication, effectiveness, safety, and compliance. e. Prioritize the patient's medication therapy problems. 	Provider Professional
<ol style="list-style-type: none"> 3. Plan: Develop an individualized patient-centered care plan in collaboration with other health care professionals and the patient/caregiver that is evidence-based and as affordable as possible. <ol style="list-style-type: none"> a. For each problem, create patient-centered goal(s) in collaboration with the patient/caregiver and other members of the healthcare team b. Develop a care plan to manage the patient's active medical conditions and resolve the identified medication therapy problems. c. Identify monitoring parameters to assess effectiveness, safety, adherence, and quality of life. 	Provider Professional

<p>4. Implement: Implement the care plan in collaboration with other health care professionals and the patient/caregiver.</p> <ol style="list-style-type: none"> a. For each condition and associated recommended strategy for resolving identified MTPs, provide the medication order in its entirety, including full drug name, dose, dosage form, route of administration, dosing interval, duration of therapy <ol style="list-style-type: none"> i. Discuss the care plan with the patient. ii. Educate the patient on his/her medications (which may include explanations of medication action, the regimen or its proper discontinuation, proper medication use and storage, expected results and when to expect them, possible adverse effects, and when and how to follow-up or seek additional care. b. Where appropriate, contribute to coordination of care by providing documentation to other providers using an evidence-based method of communication, such as SBAR (Situation, Background, Assessment, Recommendation) or SOAP (Subjective, Objective, Assessment, Plan) 	<p>Communicator Provider</p>
<p>5. Follow-up with the Patient: Monitor and evaluate the effectiveness of the care plan and modify the plan in collaboration with other health care professionals and the patient/caregiver.</p>	<p>Professional Provider</p>

Course Resources and Fees

Course Outline

See Appendix A. Please routinely check your Google campus calendar and the Canvas course site for any messages about changes in the schedule including meeting dates/times, deadlines, and room changes.

Required Textbooks/Readings

1. DiPiro, J, Talbert R, Yee G, Matzke G, Wells B, Posey L. *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill Professional, New York, NY, 12th Edition, 2023.
 - Previously used for PHA5782C
 - Available via HSC Library – Access Pharmacy
2. Other required readings will be posted in Canvas.

Use [UF VPN to access UF Libraries Resources](#) when off-campus. The UF HSC library staff can assist you with questions or issues related to accessing online library materials. For assistance contact your College of Pharmacy librarian or visit the [HSC Library Website](http://www.library.health.ufl.edu/) at this URL: <http://www.library.health.ufl.edu/>

Suggested Textbooks/Readings

- Foye WO, Lemke T, Williams DA. *Foye's Principles of Medicinal Chemistry*, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, 8th Edition, 2019. ISBN-13: 978-1496385024; ISBN-10: 1496385020
- Previously purchased for PHA5782C
 - Not available via HSC Library
- Stuart T. Haines, Thomas D. Nolin, Vicki L. Ellingrod, L. Michael Posey, Jennifer Cocohoba, Lisa Holle. *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill Professional, New York, NY, 13th Edition, 2024
- Available via HSC Library – Access Pharmacy

Other suggested readings will be posted on Canvas.

Other Required Learning Resources

N/A

Materials & Supplies Fees
N/A

Evaluation and Grading

Student Evaluation & Grading	
The Canvas© gradebook will be set-up using the percentages below to compute the grade.	
Assessment Item	Grade Percentage
iRAT (n=9; 1.25% each) Lowest score will be dropped (I.e., 8 are graded)	10%
tRAT (n=9; 1.11% each)	10%
ALS Assignment 1: Hyperlipidemia	5%
ALS Assignment 2: Asthma Action Plan	5%
Capstone	5%
Facilitated Case Discussion	5%
Exam 1	20%
Exam 2	20%
Exam 3	20%
Total	100%

Grading Scale					
Percentage	Letter Grade	Percentage	Letter Grade	Percentage	Letter Grade
92.50-100%	A	79.50-82.49%	B-	66.50-69.49%	D+
89.50-92.49%	A-	76.50-79.49%	C+	62.50-66.49%	D
86.50-89.49%	B+	72.50-76.49%	C	59.50-62.49%	D-
82.50-86.49%	B	69.50-72.49%	C-	< 59.50%	E

Rounding of grades:

Final grades in Canvas will be rounded to the 2nd decimal place. If the decimal is X.495 or higher, Canvas will round the grade to X.50. The above scale depicts this policy and grades are determined accordingly. Grade assignment is made using this policy and NO EXCEPTIONS will be made in situations where a student's grade is "close."

University of Florida Honor Pledge and Academic Dishonesty

UF students are bound by The Honor Pledge which states "We, the members of the University of Florida community, pledge to hold ourselves and our peers to the highest standards of honor and integrity by abiding by the Honor Code. On all work submitted for credit by students at the University of Florida, the following pledge is either required or implied: "On my honor, I have neither given nor received unauthorized aid in doing this assignment." The Conduct Code specifies a number of behaviors that are in violation of this code and the possible sanctions. Expectations for Artificial Intelligence and when use constitutes academic dishonesty is outlined below.

Tendering information (giving your work to another to be copied, giving someone answers to assessment questions, informing another person in a later section about the questions that appear on an assessment that you have taken, or giving or selling a paper to another student), is considered academic dishonesty.

See the [UF Conduct Code website](#) for more information. If you have any questions or concerns, please consult with the instructor or TAs in this class.

Assignment Descriptions

ALS Assignment 1: Hyperlipidemia

At the conclusion of the Active Learning Session for Hyperlipidemia (10/13) students will complete a graded assignment: students will review a hyperlipidemia patient case and then correct aspects of the Assess/Plan portion of a SOAP note. This assignment allows utilization of reference resources but is completed independently. Shared documents and applications for communication with others are not allowed during this assignment. Artificial intelligence platforms are not allowed during this assignment. This assignment is in a proctored environment, and exam policies apply to this assignment.

ALS Assignment 2: Asthma Action Plan

During the Active Learning Session on Asthma (11/5), students will be responsible for creating an asthma action plan for a patient. The purpose of the activity is to provide experience transcribing a complex medication regimen used in asthma into a digestible plan for a patient to use at home, school, or work. Students will be given details of the patient's asthma regimen and a fillable template of an asthma action plan to complete during class. This assignment is in a proctored environment, and exam policies apply to this assignment.

Course-Related Policies

UF Resources and Policies

University of Florida resources and policies can be found at this URL: <https://go.ufl.edu/syllabuspolicies>

PharmD Course Policies

The Policies in the following link apply to this course. Review the General [Pharm.D. Course Policies](http://curriculum.pharmacy.ufl.edu/current-students/course-policies/) carefully, at this URL: <http://curriculum.pharmacy.ufl.edu/current-students/course-policies/>

Attendance Policy

Attendance is mandatory for active learning sessions such as team-based learning sessions, case discussions, laboratory sessions, and other activities that the instructor designates as required. This course has 20 required sessions (ALS, Facilitated Case Discussions, Capstone). A student who misses greater than 5 session(s) for this course will receive an incomplete in the course and will retake the course during the next offering, resulting in delayed graduation.

Makeup Assignments

Makeup assignments will be required for the in-class graded assignments (Hyperlipidemia and Asthma Action Plan). Students will be required to complete the makeup assignment within one week of the missed session. Failure to complete a make-up assignment will result in a '0' for the assignment.

Late Assignments

Late assignments will not be accepted.

Educational Technology Use

The following technology below will be used during the course and the student must have the appropriate technology and software.

1. ExamSoft™ Testing Platform
2. Canvas™ Learning Management System

For technical support, navigate to [Educational Technology and IT Support Contact Information](http://curriculum.pharmacy.ufl.edu/current-students/technical-help/) at this URL: <http://curriculum.pharmacy.ufl.edu/current-students/technical-help/>

Artificial Intelligence (AI) Use for Assessments

The use of generative AI in assessments is prohibited, unless explicitly allowed by the course instructor. Assessments include any submitted work, graded or ungraded, that will be evaluated. These include, but are not limited to, quizzes, exams, assignments, writing projects, etc. If a student is uncertain about the use of AI technology, it is the student's responsibility to ask the instructor prior to beginning the assignment or assessment.

When authorized by the course director/course instructors, students may use AI technologies in the completion of an assessment if they acknowledge all use by naming the technology, describing how it was employed, and adhering to any other requirement stipulated in the assessment's instructions. Failure to acknowledge the use of AI technology or disregarding instructions related to the use of AI for assessments is considered academic misconduct. Students must disclose the use of AI and AI-assisted technologies by following the instructions below.

Application of AI technology must be done with human oversight and control, and students should carefully review and edit the result, as AI can generate outputs that can be incorrect, incomplete, or biased. **Students assume full responsibility for all content, including errors and omissions, if AI is employed.** Additionally, privacy is a concern with AI-generated content. Most commercially available AI systems are not compliant with [HIPAA](#) or FERPA protections, inputting patient or student information is prohibited by federal law.

Instructions to acknowledge the use of AI:

Statement: During the preparation of this assignment I/we, [INSERT NAME/S], used [INSERT TOOL / SERVICE] in order to [INSERT REASON OR PURPOSE]. After using this tool/service, I/we reviewed and edited the content as needed and take full responsibility for the content of the submission.

Penalties for unauthorized use:

Unauthorized use of AI text generators for assessments is considered evidence of academic dishonesty (see [policy on academic dishonesty](#)).

Disability Resource Center

Students with disabilities who experience learning barriers and would like to request academic accommodations should connect with the Disability Resource Center. See the [Get Started with the DRC webpage](#) on the Disability Resource Center site. It is important for students to share their accommodation letter with their instructor and discuss their access needs, as early as possible in the semester.

Course Evaluation Process

Students are expected to provide professional and respectful feedback on the quality of instruction in this course by completing course evaluations online. Students can complete evaluations in three ways:

1. The email they receive from GatorEvals,
2. Their Canvas course menu under GatorEvals, or
3. The central portal at <https://my-ufl.bluera.com>

Guidance on how to provide constructive feedback is available at <https://gatorevals.aa.ufl.edu/students/>. Students will be notified when the evaluation period opens. Summaries of course evaluation results are available to students at <https://gatorevals.aa.ufl.edu/public-results/>

Appendix A: Course Outline

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
		Video Other	Introduction to Patient Care 3		Katie Vogel Anderson
	1	Module	Introduction to CV Modules		Katie Vogel Anderson
	1.1	Unit	Introduction to CV Disease and Overview of Module		Eric A Dietrich
10/03/25	1.1	Lecture Video	Introduction to CV Disease and Overview of Module	31	Eric A Dietrich
	1.2	Unit	General Cardiovascular Pathophysiology (Highlight of relevant material from 1PD year)		
10/03/25	1.2.1	Lecture Video	Part 1: Heart Rate	12	Erin Bruce
10/03/25	1.2.2	Lecture Video	Part 2: Stroke Volume	14	Erin Bruce
10/03/25	1.2.3	Lecture Video	Part 3: Blood Pressure	15	Erin Bruce
10/03/25	1.2.4	Lecture Video	Part 4: Summary	3	Erin Bruce
	1.3	Unit	ASCVD Risk Assessment		Katie Vogel Anderson
10/03/25	1.3	Lecture Video	ASCVD Risk Assessment	33	Katie Vogel Anderson
		Optional/Supplemental	ASCVD Risk Calculator https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/ And PREVENT Risk Calculator: https://professional.heart.org/en/guidelines-and-statements/prevent-calculator		Katie Vogel Anderson
	2	Module	Hypertension		Katie Vogel Anderson
	2.1	Unit	Pathophysiology of Hypertension		
10/03/25	2.1	Lecture Video	Part 1: Introduction	16	Erin Bruce
10/03/25	2.1	Lecture Video	Part 2: Essential Hypertension	18	Erin Bruce

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/03/25	2.1	Lecture Video	Part 3: Risk Factors for Essential Hypertension	13	Erin Bruce
	2.1	Optional/Supplemental	Chapter 30 "Hypertension" (section title "Pathophysiology") in Pharmacotherapy: A Pathophysiologic Approach, 11e Eds. Joseph T. DiPiro, et al. New York, NY: McGraw-Hill.		Erin Bruce
	2.2	Unit	Pharmacology: Autonomic Function, Sympathetic System Drug Classes: Beta Blockers and Calcium Channel Blockers		Erin Bruce
10/06/25	2.2.1	Lecture Video	CCBs- Introduction	15	Erin Bruce
10/06/25	2.2.2	Lecture Video	Calcium Channel Blockers - MOA	11	Erin Bruce
10/06/25	2.2.3	Lecture Video	Calcium Channel Blockers - Classes and Indications	16	Erin Bruce
10/06/25	2.2.4	Lecture Video	Pharmacology of ANS: Review of ANS and Blood Pressure	23	Erin Bruce
10/06/25	2.2.5	Lecture Video	Pharmacology of ANS: Antihypertensives that target ANS	15	Erin Bruce
	2.3	Unit	Pharmacology: Renin Angiotensin System and volume Drug Classes: ACE inhibitors, ARBs, thiazide diuretics		Erin Bruce
10/06/25	2.3.1	Lecture Video	Pharmacology of Renin Angiotensin System: Review of the RAS	22	Erin Bruce

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/06/25	2.3.2	Lecture Video	Pharmacology of Renin Angiotensin System: ARBs, ACEi, and Renin inhibitors	9	Erin Bruce
10/06/25	2.3.3	Lecture Video	Pharmacology of Diuretics: Review of Renal Function	27	Erin Bruce
10/06/25	2.3.4	Lecture Video	Pharmacology of Diuretics: Loop, Thiazide, and potassium sparing diuretics	24	Erin Bruce
10/06/25	2.3	Optional/Supplemental	Hubers and Brown. Combined Angiotensin Receptor Antagonism and Nephilysin Inhibition. Circulation. 2016;133:1115-1124. (UF Libraries)		Erin Bruce
10/06/25	2.3	Optional/Supplemental	Oparil and Schmieler. New Approaches in the Treatment of Hypertension. Circulation Research. 2015;116:1074-1095. (UF Libraries)		Erin Bruce
	2.4	Unit	Medicinal Chemistry--Drug Classes: beta blockers, calcium channel blockers, ACE inhibitors, ARBS, thiazide diuretics		Xingui Liu
10/07/25	2.4.1	Lecture Video	Medicinal Chemistry of Beta Blockers and Other Adrenergic Receptors-Targeting Drugs	30	Xingui Liu
10/07/25	2.4.2	Lecture Video	Medicinal Chemistry of Calcium Channel Blockers	17	Xingui Liu
10/07/25	2.4.3	Lecture Video	Medicinal Chemistry of Drugs Targeting the Renin-Angiotensin Pathway	26	Xingui Liu
10/07/25	2.4.4	Lecture Video	Medicinal Chemistry of Diuretics	21	Xingui Liu

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/07/25	2.4	Optional/Supplemental	Ch. 17, Drugs Used to Treat Hypertensive/Hypotensive Disorders, Foye's Principles of Medicinal Chemistry, V.F. Roche, S.W. Zito, T.L. Lemke, and D.A. Williams, Eds., Wolters Kluwer, Philadelphia, PA, 8th Edition, 2020.		Xingui Liu
	2.5	Unit	Pharmacotherapy and Management of Hypertension		Katie Vogel Anderson
10/07/25	2.5.1	Lecture Video	Pharmacotherapy and Management of Hypertension Part 1: General Management	28	Katie Vogel Anderson
10/07/25	2.5.2	Lecture Video	Pharmacotherapy and Management of Hypertension Part 2: Pharmacotherapy Options	48	Katie Vogel Anderson
10/07/25	2.5.3	Lecture Video	Pharmacotherapy and Management of Hypertension Part 3: Special Populations	31	Katie Vogel Anderson
10/07/25		Optional/Supplemental	2025 Hypertension Guidelines:		Katie Vogel Anderson
	2.6	Unit	Cardiovascular Health Disparities		Lauren Carpenter
10/07/25	2.6	Lecture Video	Cardiovascular Health Disparities	24	Lauren Carpenter
	2.7	Unit	Health & Wellness: Hypertension		Katie Vogel Anderson
10/07/25	2.7	Lecture Video	Promoting Health and Wellness for Cardiovascular Health	28	Katie Vogel Anderson
10/07/25	2.7	Reading	How Can I Make My Lifestyle Healthier? (PDF)		Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/07/25	2.7	Optional/Supplemental	Life's Essential 8: https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8		Katie Vogel Anderson
10/8/25 from 10am-11:50am	2	Active Learning Session	ALS 1: Hypertension (2hr)	50	Erin Bruce, Katie Vogel Anderson, Lauren Carpenter, Xingui Liu
	2	Quiz (iRAT/tRAT)	ALS 1 iRAT/tRAT		Katie Vogel Anderson
10/8/25 from 1pm- 2:50pm	2	Active Learning Session	ALS 2: Hypertension (2hr)	50	Erin Bruce, Katie Vogel Anderson, Lauren Carpenter, Xingui Liu
	3	Module	Dyslipidemia		Eric A Dietrich
	3.1	Unit	Dyslipidemia – Lipid Metabolism		Bradley Phillips
10/08/25	3.1	Lecture Video	Lipid Metabolism	13	Bradley Phillips
10/08/25	3.1	Video Other	Physiology of Lipoproteins Cholesterol https://www.youtube.com/watch?v=PkkH8ITxvzA	11	Bradley Phillips
10/08/25	3.1	Optional/Supplemental	Pharmacotherapy A Pathophysiologic Approach, 13e; Chapter 35: Pathophysiology Section (Access Pharmacy)		Bradley Phillips
10/08/25	3.1	Optional/Supplemental	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14e; Chapter 37: Plasma Lipoprotein Metabolism Section (Access Pharmacy)		Bradley Phillips
	3.2	Unit	Dyslipidemia - Pharmacology		Bradley Phillips
10/08/25	3.2.1	Lecture Video	Pharmacology of Antihyperlipidemic Agents Part 1: Intro	3	Bradley Phillips

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/08/25	3.2.2	Lecture Video	Pharmacology of Antihyperlipidemic Agents Part 2: Statins	17	Bradley Phillips
10/08/25	3.2.3	Lecture Video	Pharmacology of Antihyperlipidemic Agents Part 3: CV Agents	21	Bradley Phillips
10/08/25	3.2.4	Lecture Video	Pharmacology of Antihyperlipidemic Agents Part 4: Additional Agents	22	Bradley Phillips
10/08/25	3.2	Optional/Supplemental	Key Recommendations to Reduce the Risk of Atherosclerotic Cardiovascular Disease Table 31-4 (Access Pharmacy)		Bradley Phillips
10/08/25	3.2	Optional/Supplemental	Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14e; Chapter 37: Drug Therapy for Dyslipidemia (Access Pharmacy)		Bradley Phillips
10/08/25	3.2	Optional/Supplemental	2018 ACC-AHA Guidelines on Management of Blood Cholesterol		Bradley Phillips
10/08/25	3.2	Optional/Supplemental	2019 ACC-AHA Guideline on the Primary Prevention of Cardiovascular Disease		Bradley Phillips
	3.3	Unit	Medicinal Chemistry of Antihyperlipidemics		Guangrong Zheng
10/09/25	3.3.1	Lecture Video	Medicinal Chemistry of Antihyperlipidemics Part 1	27	Guangrong Zheng
10/09/25	3.3.2	Lecture Video	Medicinal Chemistry of Antihyperlipidemics Part 2	18	Guangrong Zheng
	3.4	Unit	Management of Dyslipidemia		Eric A Dietrich

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/09/25	3.4.1	Lecture Video	Part 1: Background and Goals of Treatment	9	Eric A Dietrich
10/09/25	3.4.2	Lecture Video	Part 2: Statin Therapy	29	Eric A Dietrich
10/09/25	3.4.3	Lecture Video	Part 3: Non-Statins Therapies	20	Eric A Dietrich
10/09/25	3.4.4	Lecture Video	Part 4: Treatment and Monitoring	22	Eric A Dietrich
10/09/25	3.4.5	Lecture Video	Part 5: Patient Cases and Summary	14	Eric A Dietrich
	3.5	Unit	Informatics: HIT Supporting Outpatient Drug Use		
10/10/25	3.5	Lecture Video	Health IT and Informatics	25	Je-Won Hong, Khoa Nguyen
	3.6	Unit	Interprofessional Communications & Collaboration: Shared Decision Making		Eric A Dietrich

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/10/25	3.6	Lecture Video	Shared Decision Making	20	Eric A Dietrich
10/13/25 from 10am-11:50am	3	Active Learning Session	ALS 3: Hyperlipidemia	50	Bradley Phillips, Eric A Dietrich, Guangrong Zheng
	3	Quiz (iRAT/tRAT)	ALS 2 iRAT/tRAT		Eric A Dietrich
10/13/25 from 1pm-2:50pm	3	Active Learning Session	ALS 4: Hyperlipidemia	50	Bradley Phillips, Eric A Dietrich, Guangrong Zheng
Due In Class	3	Assignment Graded	Individual In-Class Assignment: Hyperlipidemia		Eric A Dietrich
	4	Module	Chronic Coronary Disease		Katie Vogel Anderson
	4.1	Unit	Pathophysiology of Chronic Coronary Disease		
10/13/25	4.1.1	Lecture Video	Part 1: Review of Coronary Blood Flow	15	Erin Bruce
	4.1.2	Lecture Video	Part 2: Pharmaceutical Treatments	25	Erin Bruce
	4.2	Unit	Pharmacology and Medicinal Chemistry of Nitrodilators		Mohamed Osman Radwan
10/13/25	4.2	Lecture Video	Pharmacology and Medicinal Chemistry of Nitrodilators	48	Mohamed Osman Radwan
	4.3	Unit	Management of Chronic Coronary Disease		Katie Vogel Anderson
10/13/25	4.3	Lecture Video	Management of Chronic Coronary Disease (aka. Ischemic Heart Disease)	60	Katie Vogel Anderson
10/13/25	4.3	Optional/Supplemental	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with Chronic Coronary Disease		Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/13/25	4.3	Optional/Supplemental	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140:e596–e646.		Katie Vogel Anderson
	4.4	Unit	Evidence-based Practice: Cardiovascular Clinical Trials		Julio Duarte
10/13/25	4.4	Lecture Video	Cardiovascular Clinical Trials	30	Julio Duarte
10/13/25	4.4	Reading	Munkhaugen 2025 - Beta-Blockers after MI in Patients without Heart Failure; Ibanez 2025 - Beta-Blockers after MI without Reduced Ejection Fraction	40	Julio Duarte
10/15/25 from 2pm-3:50pm		Facilitated Case Discussion	Facilitated Case Discussion: Hypertension	50	Eric A Dietrich, Erin Lyn St Onge, Jason Powell, Katie Vogel Anderson
10/16/25 from 10am-11:50am	4	Active Learning Session	ALS 5: Ischemic Heart Disease	50	Erin Bruce, Katie Vogel Anderson, Mohamed Osman Radwan
	4	Quiz (iRAT/tRAT)	ALS 3 iRAT/tRAT		Julio Duarte
10/16/25 from 1pm-2:50pm	4	Active Learning Session	ALS 6: Ischemic Heart Disease	50	Julio Duarte, Katie Vogel Anderson
10/20/25 from 2pm-4pm	1 - 4	Exam	Exam 1	100	Katie Vogel Anderson
	5	Module	Anticoagulation and Acute Coronary Syndrome		Katie Vogel Anderson
	5.1	Unit	Pathophysiology of Blood Clotting		Katie Vogel Anderson
10/16/25	5.1	Lecture Video	Pathophysiology of Blood Clotting	16	Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/16/25	5.1	Reading	Plaque Rupture and Clot Formation	5	Katie Vogel Anderson
10/16/25	5.1	Reading	Ch. 38 Venous Thromboembolism - Pathophysiology section (DiPiro)	15	
	5.2	Unit	Pharmacology of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy		Katie Vogel Anderson
10/16/25	5.2	Lecture Video	Pharmacology of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy	42	Katie Vogel Anderson
	5.3	Unit	Personalized Medicine: Cardiovascular Diseases		Larisa Humma Cavallari
10/17/25	5.3	Lecture Video	Personalized Medicine—Cardiovascular Diseases	69	Larisa Humma Cavallari
10/17/25	5.3	Optional/Supplemental	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022. doi:10.1002/cpt.2526.		Larisa Humma Cavallari
10/17/25	5.3	Optional/Supplemental	Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021.		Larisa Humma Cavallari
10/17/25	5.3	Optional/Supplemental	Chapter e7. Clinical Pharmacogenomics. In Joseph T. DiPiro, et al: Pharmacotherapy: A Pathophysiologic Approach, 12e: Polymorphisms in Genes for Drug-Metabolizing Enzymes section: CYP2C19; Polymorphisms in Drug Transporter Genes.		Larisa Humma Cavallari
	5.4	Unit	Medicinal Chemistry of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy		Mohamed Osman Radwan

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/17/25	5.4	Lecture Video	Medicinal Chemistry of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy	56	Mohamed Osman Radwan
10/17/25	5.4	Optional/Supplemental	Section 3, Chapter 18 - Foye's Principles of Medicinal Chemistry, 8th edition		Mohamed Osman Radwan
	5.5	Unit	Management of Acute Coronary Syndrome		Katie Vogel Anderson
10/20/25	5.5	Lecture Video	Management of Acute Coronary Syndrome	46	Katie Vogel Anderson
10/20/25	5.5	Optional/Supplemental	Interactive Cardiovascular Library Content: Coronary Stent		Katie Vogel Anderson
10/20/25	5.5	Optional/Supplemental	NSTEMI Guidelines, 2014		Katie Vogel Anderson
10/20/25	5.5	Optional/Supplemental	STEMI Guidelines, 2013		Katie Vogel Anderson
10/22/25 from 1pm-2:50pm	5	Active Learning Session	ALS 7: ACS (3 Hours)	50	Cameron Thomas, Katie Vogel Anderson, Mohamed Osman Radwan
	5	Quiz (iRAT/tRAT)	ALS 4 iRAT/tRAT		Katie Vogel Anderson
10/23/25 from 10am-11:50am	5	Facilitated Case Discussion	Zoom - Facilitated Case Discussion - ACS	100	Bethany Shoulders, Eric A Dietrich, Erin Lyn St Onge, Jason Powell, Karen Whalen, Katie Vogel Anderson
	6	Module	Heart Failure		Julio Duarte
	6.1	Unit	Pathophysiology of Heart Failure		

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/23/25	6.1	Lecture Video	Pathophysiology of Heart Failure	42	Julio Duarte
	6.2	Unit	Pharmacology of Inotropic Agents, Glycosides, Nephilysin Inhibitors, Aldosterone Antagonists		
10/23/25	6.2	Lecture Video	Pharmacology of Treatment of Heart Failure	26	Julio Duarte
	6.3	Unit	Medicinal Chemistry of Inotropic Agents, Glycosides, Aldosterone Antagonists		Mohamed Osman Radwan
10/23/25	6.3	Lecture Video	Medicinal Chemistry of Inotropic Agents, Glycosides, Aldosterone Antagonists	45	Mohamed Osman Radwan
	6.3	Optional/Supplemental	Section 3, Chapter 16 - Foye's Principles of Medicinal Chemistry, 8th edition		Mohamed Osman Radwan
	6.4	Unit	Management of Chronic Heart Failure (HFrEF & HFpEF)		Julio Duarte
10/24/25	6.4.1	Lecture Video	Heart Failure Part 1: HFrEF	56	Julio Duarte
10/24/25	6.4.2	Lecture Video	Heart Failure Part 2: HFpEF	48	Julio Duarte
10/24/25	6.4	Optional/Supplemental	2022 AHA/ACC/HFSA Guidelines for the Management of Heart Failure. Circulation. 2022 May 3;145(18):e895-e1032.		Julio Duarte
	6.5	Unit	Patient Safety/Med Errors; Root Cause Analysis: Medication Reconciliation		Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/24/25	6.5	Lecture Video	Medication Reconciliation	18	Katie Vogel Anderson
10/24/25	6.5	Reading	Medication Reconciliation Reading	10	Katie Vogel Anderson
10/27/25 from 10am-11:50am	6	Active Learning Session	ALS 8: Heart Failure	50	Julio Duarte
	6	Quiz (iRAT/tRAT)	ALS 5 iRAT/tRAT		
10/27/25 from 1pm-2:50pm	6	Active Learning Session	ALS 9: Heart Failure	50	Julio Duarte, Katie Vogel Anderson, Mohamed Osman Radwan
	7	Module	Anticoagulation & Arrhythmias		Katie Vogel Anderson
	7.1	Unit	VTE		Katie Vogel Anderson
10/27/25	7.1	Lecture Video	Venous Thromboembolism (VTE)	52	Katie Vogel Anderson
	7.2	Unit	Warfarin and Heparin Dosing (AKA. Individualized Anticoagulant Dosing)		Katie Vogel Anderson
10/27/25	7.2	Lecture Video	Warfarin and Heparin Dosing (AKA. Individualized Anticoagulant Dosing)	44	Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/27/25	7.2	Optional/Supplemental	WarfarinDosing.org http://warfarindosing.org/Source/Home.aspx		Katie Vogel Anderson
	7.3	Unit	Personalized Medicine CV: Warfarin Pharmacogenetics		Larisa Humma Cavallari
10/27/25	7.3	Lecture Video	Personalized Medicine CV: Warfarin Pharmacogenetics	31	Larisa Humma Cavallari
10/27/25	7.3	Optional/Supplemental	Clinical Pharmacogenetics Implementation Consortium Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017 Sep;102(3):397-404.		Larisa Humma Cavallari
10/27/25	7.3	Optional/Supplemental	Chapter e7. Clinical Pharmacogenomics. In Joseph T. DiPiro, et al: Pharmacotherapy: A Pathophysiologic Approach, 12e: Polymorphisms in Genes for Drug-Metabolizing Enzymes: CYP2C9; Polymorphisms in Drug Target Genes: Enzyme Genes and Medication Response.		Larisa Humma Cavallari
	7.4	Unit	Pathophysiology of Arrhythmias		Katie Vogel Anderson
10/28/25	7.4.1	Lecture Video	Pathophysiology of Arrhythmias Part 1: Reviews of Normal ECG, Definitions, Mechanisms of Bradycardia	25	Katie Vogel Anderson
10/28/25	7.4.2	Lecture Video	Pathophysiology of Arrhythmias Part 2: Mechanisms of Tachycardias	35	Katie Vogel Anderson
	7.5	Unit	Introduction to Electrocardiology		Katie Vogel Anderson
10/28/25	7.5	Lecture Video	Introduction to Electrocardiology	22	Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
10/28/25	7.5	Reading	DiPiro Chapter 1 - ECG section ONLY (Access Pharmacy)	15	Katie Vogel Anderson
	7.6	Unit	Pharmacology of Antiarrhythmics & Pharmacokinetics of Digoxin and Antiarrhythmics		Katie Vogel Anderson
10/29/25	7.6	Lecture Video	Pharmacology of Antiarrhythmics & Pharmacokinetics of Digoxin and Antiarrhythmics	26	Katie Vogel Anderson
	7.7	Unit	Medicinal Chemistry of Antiarrhythmics		Mohamed Osman Radwan
10/29/25	7.7	Lecture Video	Medicinal Chemistry of Antiarrhythmics	35	Mohamed Osman Radwan
10/29/25	7.7	Optional/Supplemental	Section 3, Chapter 16 - Foye's Principles of Medicinal Chemistry, 8th edition		Mohamed Osman Radwan
	7.8	Unit	Management of Arrhythmias		Katie Vogel Anderson
10/29/25	7.8	Lecture Video	Management of Arrhythmias	51	Katie Vogel Anderson
10/30/25 from 10am-11:50am	7	Active Learning Session	ALS 10: Atrial Fibrillation	50	Katie Vogel Anderson, Larisa Humma Cavallari, Mohamed Osman Radwan
	7	Quiz (iRAT/tRAT)	ALS 6 iRAT/tRAT		Katie Vogel Anderson
10/31/25 from 10am-11:50am		Facilitated Case Discussion	Zoom: Facilitated Case Discussion - AFIB/VTE Case Discussion	100	Eric A Dietrich, Erin Lyn St Onge, Karen Whalen, Katie Vogel Anderson, Tracy Leonard
11/3/25 from 2pm-4pm	5-7	Exam	Exam 2	100	Katie Vogel Anderson

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
	8	Module	Asthma		Bradley Phillips
	8.1	Unit	Pathophysiology of Asthma		Bradley Phillips
11/03/25	8.1	Lecture Video	Asthma Pathophysiology, Clinical Presentation, Diagnosis	27	Bradley Phillips
11/03/25	8.1	Optional/Supplemental	Resource link to the wheezing sound found in lecture		Bradley Phillips
11/03/25	8.1	Optional/Supplemental	Pharmacotherapy: A Pathophysiologic Approach, 12e; Chapter 44: Asthma.(Access Pharmacy)		Bradley Phillips
	8.2	Unit	Pharmacology of Antiasthmatics and COPD		Francine Azeredo
11/03/25	8.2.1	Lecture Video	Pharmacology of corticosteroids	25	Francine Azeredo
11/03/25	8.2.2	Lecture Video	Pharmacology of beta agonists	25	Francine Azeredo
11/03/25	8.2.3	Lecture Video	Pharmacology of antimuscarinics and Other Drugs for Asthma and COPD	15	Francine Azeredo
11/03/25	8.2.4	Lecture Video	Pharmacology of monoclonal antibodies	15	Francine Azeredo
	8.3	Unit	Medicinal Chemistry of Oral and Inhaled Corticosteroids, Short-acting Beta-agonists, Long-acting Beta-agonists, Muscarinic Agents		Jane V Aldrich
11/03/25	8.3.1	Lecture Video	Medicinal Chemistry of Beta Agonists	16	Jane V Aldrich

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
11/03/25	8.3.2	Lecture Video	Medicinal Chemistry of Corticosteroids	22	Jane V Aldrich
11/03/25	8.3.3	Lecture Video	Medicinal Chemistry of Antimuscarinics and Other Drugs for Asthma and COPD	18	Jane V Aldrich
11/03/25	8.3.4	Lecture Video	Monoclonal Antibodies	9	Jane V Aldrich
	8.4	Unit	Management of Chronic Asthma		Bradley Phillips
11/04/25	8.4.1	Lecture Video	Pharmacotherapy Overview for Chronic Asthma	27	Bradley Phillips
11/04/25	8.4.2	Lecture Video	Asthma Assessment	15	Bradley Phillips
11/04/25	8.4.3	Lecture Video	Treating Chronic Asthma	18	Bradley Phillips
11/04/25	8.4.4	Lecture Video	Treating Asthma Exacerbations	17	Bradley Phillips
11/04/25	8.4	Reading	GINA Treatment Algorithms 2025	30	Bradley Phillips
11/04/25	8.4	Reading	Asthma Action Plan	15	Bradley Phillips
11/04/25	8.4	Optional/Supplemental	Respiratory Treatments		Bradley Phillips

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
11/04/25	8.4	Optional/Supplemental	GINA 2025 - Global Strategy for Asthma Management		Bradley Phillips
11/04/25	8.4	Optional/Supplemental	Inhaler Education		Bradley Phillips
11/04/25	8.4	Optional/Supplemental	How to use a spacing device		Bradley Phillips
11/5/25 from 10am-11:50am	8	Active Learning Session	ALS 11: Asthma (2hr workup)	50	Bradley Phillips, Francine Azeredo, Jane V Aldrich
	8	Quiz (iRAT/tRAT)	ALS 7 iRAT/tRAT		Bradley Phillips
11/5/25 from 1pm-2:50pm	8	Active Learning Session	ALS 12: Asthma (2hr workup)	50	Bradley Phillips, Francine Azeredo, Jane V Aldrich
	8	Assignment Graded	Individual Assignment: Asthma Action Plan		Bradley Phillips
	9	Module	COPD		Michelle Farland
	9.1	Unit	Pathophysiology of COPD		Michelle Farland
11/05/25	9.1	Lecture Video	COPD Pathophysiology, Clinical Presentation, Diagnosis	33	Michelle Farland
11/05/25	9.1	Optional/Supplemental	Sound of a smoker cough		Michelle Farland
	9.2	Unit	Management of COPD		Michelle Farland
11/05/25	9.2	Lecture Video	COPD Management	58	Michelle Farland
	9.3	Unit	Health & Wellness: Smoking Cessation		Bradley Phillips

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
11/05/25	9.3.1	Lecture Video	Smoking Cessation - Background	28	Bradley Phillips
11/05/25	9.3.2	Lecture Video	Smoking Cessation - Pharmacotherapy	41	Bradley Phillips
11/05/25	9.3	Optional/Supplemental	2018 ACC Expert Consensus Decision: Pathway on Tobacco Cessation Treatment		Bradley Phillips
11/05/25	9.3	Optional/Supplemental	Initiating Pharmacologic Treatment in Tobacco-Dependent Adults		Bradley Phillips
11/05/25	9.3	Optional/Supplemental	FDA Approved Smoking Cessation Medications		Bradley Phillips
	9.4	Unit	Communications - Patients: Motivational Interviewing		Teresa Elaine Roane
11/06/25	9.4	Lecture Video	Introduction to ComMit eLearning Modules	13	Teresa Elaine Roane
11/06/25	9.4	Video Other	ComMit Module 3: Sense-Making and Practical Reasoning		Teresa Elaine Roane

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
	9.5	Unit	Specialized Populations: Geriatric Drug Dosing		Katie Vogel Anderson
11/06/25	9.5	Lecture Video	Geriatric Drug Dosing Considerations	26	Katie Vogel Anderson
	9.6	Unit	Evidence-Based Practice: Cohort Studies and Confounding and Bias		Sebastian Jugl
11/06/25	9.6	Lecture Video	Evidence-Based Practice—Cohort Studies and Confounding & Bias	35	Sebastian Jugl
11/06/25	9.6	Reading	A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD (PDF) (Sections to read: Abstract, Article Summary, Methods, Tables 1, 2, and 3 (focusing on results of any death, angina, myocardial infarction and stroke) and Discussion, paragraph 9.)	25	Sebastian Jugl
11/7/25 from 10am-11:50am	9	Active Learning Session	ALS 13: COPD	50	Michelle Farland, Teresa Elaine Roane
	9	Quiz (iRAT/tRAT)	ALS 8 iRAT/tRAT		Michelle Farland
11/7/25 from 1pm- 2:50pm	9	Active Learning Session	ALS 14: COPD	50	Michelle Farland, Teresa Elaine Roane
	10	Module	Respiratory Conditions		Kaitlin Alexander
	10.1	Unit	Hospital-Acquired & Ventilator-Associated Pneumonias		Kaitlin Alexander
11/07/25	10.1	Lecture Video	Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia	45	Kaitlin Alexander
11/07/25	10.1	Optional/Supplemental	Lower Respiratory Tract Infections. In: DiPiro Pharmacotherapy: A Pathophysiologic Approach, 13e. McGraw Hill; 2024. (Chapter 134 – ONLY section on Pneumonia)		Kaitlin Alexander

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
11/07/25	10.1	Optional/Supplemental	Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63: 1-51.		Kaitlin Alexander
	10.2	Unit	Cough & Cold (re-enforce from Patient Care 1)		
11/07/25	10.2	Lecture Video	Cough and Cold	39	Bradley Phillips
11/07/25	10.2	Video Other	How to Use a Nasal Spray (https://www.youtube.com/watch?v=ICqBAN28Tgo)		Bradley Phillips
	10.3	Unit	Interprofessional Communication: Listen actively, and encourage ideas and opinions of other interprofessional team members.		Carol Anne Motycka
11/10/25	10.3	Lecture Video	Interprofessional Communication - Embracing Interprofessional Teamwork to Improve Patient Safety Through TeamSteps	45	Carol Anne Motycka
	10.4	Unit	Lung Cancer		David DeRemer
11/10/25	10.4	Lecture Video	Lung Cancer	55	David DeRemer
11/12/25 from 10am-11:50am	10	Active Learning Session	ALS 15: Respiratory Conditions	50	Bradley Phillips, Carol Anne Motycka, David DeRemer, Kaitlin Alexander
	10	Quiz (iRAT/tRAT)	ALS 9 iRAT/tRAT 9		Kaitlin Alexander
11/12/25 from 1pm-2:50pm	10	Active Learning Session	ALS 16: Respiratory Conditions	50	Bradley Phillips, Carol Anne Motycka, David DeRemer, Kaitlin Alexander

Date / Time [Recommended for Independent Study]	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
11/14/25 from 1pm-5pm	1-10	Active Learning Session	PC 3 Capstone (4hr workup)	200	Katie Vogel Anderson
	1-10	Assignment Graded	Capstone Assignment Submission		Eric A Dietrich, Julio Duarte, Kaitlin Alexander, Katie Vogel Anderson
11/25/25 from 2pm-4pm	8-10	Exam	Exam 3		Katie Vogel Anderson
		Exam Review	Final Exam Review		
			Total Contact Hours:	82	